- Home
- JANX vs AZTA Comparison
JANX vs AZTA Comparison
Compare JANX & AZTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JANX
- AZTA
- Stock Information
- Founded
- JANX 2017
- AZTA 1978
- Country
- JANX United States
- AZTA United States
- Employees
- JANX N/A
- AZTA N/A
- Industry
- JANX Biotechnology: Pharmaceutical Preparations
- AZTA Industrial Machinery/Components
- Sector
- JANX Health Care
- AZTA Technology
- Exchange
- JANX Nasdaq
- AZTA Nasdaq
- Market Cap
- JANX 1.4B
- AZTA 1.4B
- IPO Year
- JANX 2021
- AZTA 1995
- Fundamental
- Price
- JANX $24.87
- AZTA $30.08
- Analyst Decision
- JANX Strong Buy
- AZTA Buy
- Analyst Count
- JANX 8
- AZTA 4
- Target Price
- JANX $90.63
- AZTA $42.00
- AVG Volume (30 Days)
- JANX 892.8K
- AZTA 716.2K
- Earning Date
- JANX 08-07-2025
- AZTA 08-05-2025
- Dividend Yield
- JANX N/A
- AZTA N/A
- EPS Growth
- JANX N/A
- AZTA N/A
- EPS
- JANX N/A
- AZTA N/A
- Revenue
- JANX $439,000.00
- AZTA $668,821,000.00
- Revenue This Year
- JANX N/A
- AZTA N/A
- Revenue Next Year
- JANX $1,470.83
- AZTA $4.74
- P/E Ratio
- JANX N/A
- AZTA N/A
- Revenue Growth
- JANX N/A
- AZTA 12.46
- 52 Week Low
- JANX $21.97
- AZTA $23.91
- 52 Week High
- JANX $71.71
- AZTA $55.64
- Technical
- Relative Strength Index (RSI)
- JANX 51.13
- AZTA 49.73
- Support Level
- JANX $23.96
- AZTA $27.95
- Resistance Level
- JANX $25.93
- AZTA $32.26
- Average True Range (ATR)
- JANX 1.55
- AZTA 1.56
- MACD
- JANX 0.06
- AZTA -0.09
- Stochastic Oscillator
- JANX 61.91
- AZTA 53.45
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
About AZTA Azenta Inc.
Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has three reportable segments that are Sample Management Solutions, Multiomics, and B Medical Systems. It generates a substantial part of its revenue from its Sample Management Solutions segment.